Fortrea’s Gani Chico Talks Oncology Innovation, AI and Clinical Trial Strategy

In a compelling new interview with Fierce Biotech, Isagani “Gani” Chico, vice president and global head of oncology therapeutic expertise at Fortrea, shares insights on the evolving oncology drug development landscape and the strategic role of contract research organizations (CROs).

Chico outlines four critical shifts impacting oncology research: scientific innovation, tighter economic constraints, evolving regulatory demands and growing social pressure to diversify patient representation. He highlights how new drug mechanisms and trial designs—such as basket and umbrella trials—are reshaping the path to approval.

Artificial intelligence is also transforming clinical development. Chico describes how Fortrea uses AI to analyze patient data for improved biomarker identification and trial efficiency, helping predict outcomes and streamline enrollment.

Fortrea, he notes, leverages decades of data and patient enablement tools to enhance trial flexibility. Their models—ranging from full-service to hybrid approaches—offer sponsors scalable solutions that maintain high standards while accelerating timelines.

Chico emphasizes that beyond tech and data, deep therapeutic expertise remains the cornerstone of impactful decision-making in oncology trials.

Watch the full interview to hear Chico’s perspective on what’s next in oncology R&D and how Fortrea is helping shape it.